Try our Advanced Search for more refined results
Life Sciences - December, 2009
147 articles
- AstraZeneca Unit Pulls H1N1 Vaccines
- Breg Braces For Bledsoe Patent Suit
- Rigel Securities Suit Tossed On Specificity Grounds
- Roche's Mircera Banned From U.S. In Amgen's Win
- Genzyme Board Sued Over Drug Delays, Insider Deals
- Schering Sues Apotex Over Nasonex ANDA
- NY Court Boots Ga. Man's Lipitor Case Against Pfizer
- Ill. Drug-Flushing Law Takes Effect In New Year
- Q&A With Burns & Levinson's Josef Volman
- Class Cert. Sought In Suit Over 'Snake-Oil' CVS Item
- 3rd Circ. Vacates Class Cert. In Schering ERISA Suit
- Fosamax MDL Plaintiff Takes Case To 2nd Circ.
- Lupin Gets Namenda License In Forest Settlement
- Negligence Claims Against J&J, Subsidiary Dismissed
- Lilly To Pay Up To $755M For Autoimmune Treatments
- Sex Bias Plaintiffs Seek Sanctions Against Novartis
- Actelion To Lose $80M After Arbitration Ruling
- Abbott Hits Sandoz On Generic Nimbex In Del., NJ
- Former Biovail CFO Settles In SEC Fraud Suit
- Schering Targets Mylan Over Vytorin ANDA
- Have You Reviewed Your Royalty Agreements Lately?
- Abbott Appeals $1.9B Hit In Patent Suit Over Humira
- Cephalon Loses Round In JHU Leukemia Patent Suit
- Boehringer Tries To Derail Mirapex Antitrust Suits
- DLA Piper Ex-Partner Opens Anti-Counterfeiting Firm
- Sanofi-Aventis Snaps Up Chattem For $1.9B
- Medical Suppliers Resolve Marketing Dispute
- Senate Moves Forward With Health Care Vote
- Pfizer Puts $6M Down On Rights To Stem Cell Therapy
- Bayer Wins Ill. Class Action Over Baycol Marketing
- Dr. Reddy's Loses Zyprexa Patent Fight In UK Court
- Interest Pushes Humira Award Up To $1.85B
- 2nd Circ. Won't Force HPV Test Reclassification
- Q&A With Choate's Robert Frank Jr.
- Jury Invalidates Hologic Patents In Suit Against Rival
- Merck Singulair Patent Survives USPTO Re-Exam
- The Medicines Co. Issues Blood Pressure Drug Recall
- Pfizer Execs Seek Dismissal Of Derivative Suit
- Still In Hot Seat, FDA Opens Mexico City Outpost
- Amgen Says ERISA Anemia Drug Claims Lack Merit
- Schering Settles Medi-Cal Fraud Suit For $21M
- Ethicon To Snap Up Acclarent For $785M
- South Florida Reclaims Place As Top 'Judicial Hellhole'
- Cephalon Files 3rd Suit Over Planned Generic Nuvigil
- Hospira Adds Orchid Generic Antibiotic Unit For $400M
- FDA Warns Abbott Unit Over Eye Device Manufacturing
- Md. Insurance Boss To Join FDA As Chief Counsel
- AstraZeneca Loses Appeal In Generic Prilosec Feud
- SEC Drops Anthrax Civil Case Against Convicted Exec
- Sales Reps Hit Sanofi With Overtime Action
- Bellwether Consolidation Denied In Levaquin MDL
- Appeals Court Nixes Vioxx Plaintiffs' Class Cert. Bid
- Senators Reject Drug Importation Measure
- Pfizer, Businessman Settle Viagra Missile Suit
- Abbott To Buy Starlims In $123M Cash Deal
- Research Tools Sail Out Of The Safe Harbor
- Sanofi Recalls Weakening Swine Flu Vaccine Doses
- Blood Processing Co. Sues Rival Again Over Centrifuge
- Wellbutrin Indirect Buyers Seek Cert. In Antitrust Suit
- Inequitable Conduct Still In Play In Crestor Suit
- Judge Chucks NeuroMetrix Shareholder Action
- WellNx Diet Pill Marketing Fraud Suit Survives
- NuvaRing Judge Scolds Defense Over Slew Of Motions
- USPTO Declares Stem Cell Patent Interference
- Bayer Once More Defending Trasylol In Federal Court
- Biotech Co. Given Chance To Fix Mintz Levin Suit
- King Pharm.'s Advertising Suit Against Rival Hits Snag
- Some Counterclaims Tossed In Roche Suit Over Xeloda
- Is There A Written Description Requirement After All?
- GSK Forced To Turn Over Docs In Avandia MDL
- Q&A With Lowenstein Sandler's Douglas Eakeley
- P&G's Crest Whitestrips Targeted In Patent Suit
- Novartis, Bayer Near Deal Over Hemophilia Drugs
- SEC Kicks Off Wide Insider Trading Investigation
- Judge Rebuffs Teva Discovery Bid In Aricept IP Suit
- FDA Panel Finds Fatal Risks In GE, Covidien MRI Drugs
- FDA Questions Low-Cost Drug Import Legislation
- FDA Warns Sorin Over Inadequate Incident Reports
- FDA Should Beef Up Post-Market Drug Safety: GAO
- Bayer Recalls Alka-Seltzer Gel Caps Over Mislabeling
- EU Raids Lundbeck, Others In Antitrust Probe
- Patent Pools In The Life Sciences
- Mylan, Wyeth Reach Accord On Effexor XR
- Actavis Loses Bid To Toss Generic Reglan Claim
- CORRECTED: Diversity Of Clients Puts Skadden On Top
- Lilly, 3rd-Party Payor Class Argue Zyprexa Appeal
- Clarity In Chinese Merger Review Procedures?
- Medtronic 'Denies Reality' In Pacemaker Case: Judge
- House Panel Raises Alarms Over Drug Price Increases
- Ranbaxy Admits To Infringing Purdue OxyContin Patent
- Fed. Circ. Nixes Tyco Ultrasonic Device Patent Suit
- Cephalon Sues Teva Over Plan For Generic Nuvigil
- FDA Issues Warning On Voltaren Gel Liver Risks
- Mayer Brown 1st-Years Asked To Sit Tight Till Oct. 2010
- Combating Abusive Pleading With Iqbal/Twombly
- Celgene To Snap Up Gloucester Pharma For $640M
- Unilever Settles Potassium Supplement Suit For $1.4M
- Sens. Reject Limit On Medical Malpractice Attys' Fees
- 11th Circ. Upholds Toss Of Solvay Marketing Suit
- Conn. AG To Probe Health Net-UnitedHealth Deal
- $14M Deal Wins Final OK In Long-Running Dura Case
- Steris In Hot Water Again Over Sterilization Device
- FDA Asked To Look At Drugs' Impact On Child Weight
- Biogen Angles For Facet With 2nd Hostile Bid
- Merck KGaA Wants Brookstone's 'False Generic' Yanked
- Shook Hardy Keeps Clients Coming Back
- Teva, Mylan Clarify Copaxone Patent Claims
- IP Attorneys Dominate At Fish & Richardson
- Finnegan Stays No. 1 In Downturn
- Pharmacies' Suit Over Pfizer-Wyeth Merger Dismissed
- Financial Discipline Keeps Wilson Sonsini On Top
- Product Liability Attorneys Dominate At Bowman Brooke
- Another Darby & Darby Atty Leaves For McDermott
- Ariad V. Eli Lilly And Written Description Requirement
- Matrixx, Capricorn Resolve Zicam Contract Spat
- Pfizer Adds New Suit To Litigation Over Lipitor ANDAs
- Kohl Pitches Stricter Pay-For-Delay Drug Rules
- Sanofi-Aventis Warns Of Norpramin Heart Attack Risk
- Sonnenschein Scores Dickstein Corporate Partner
- GSK Warns Of HIV Drug's Heart Attack Risk
- Roche Wins Transfer Of Novartis' Patent Case To NC
- Consumer Group Seeks Ban Of Abbott's Meridia Drug
- McDermott Snags Biotech Atty From Fish & Richardson
- Takeda Sues Watson Over Sleeping Pill ANDA
- AstraZeneca Links Up With Targacept In $1.2B Deal
- Direct Purchasers Propose Counsel In AndroGel MDL
- Q&A With Finnegan's J. Michael Jakes
- Fed. Circ. Nixes $15M Infringement Ruling V. Arthrex
- Boston Scientific Settles ERISA Suit For $8M
- PBM Wins $13.5M In Baby Formula Advertising Suit
- Court Says Suit Over Stryker Hip Implant Preempted
- Judge Won't Compel Boston Scientific Privileged Docs
- Investor Sues Hemispherx As FDA Denies Fatigue Drug
- Panel Nixes Pfizer Fraudulent Marketing MDL
- Judge Rips Fosamax MDL Lawyers' Spat Over Clients
- Zimmer Securities Fraud Class Action Gets The Boot
- 6th Circ. Affirms Dismissals From Novartis MDL
- Shire, Teva Settle Contract Spat Over Adderall Supplies
- Suits Over Novartis Eczema Drug Return To NJ Court
- Bayer Buys Cancer-Fighting Antibody Rights For $426M
- Sidley Austin Starts Up Silicon Valley Office
- Judge Guts State's 'Slash And Burn' Zyprexa Suit
- Duane Morris Snags Fish & Richardson IP Principal
- 21 States Win $25M Settlement In Vitamin Suit
- Stryker Buys Medical Device Firm Ascent For $525M
- European Vioxx Claims Don't Stand In US: 5th Circ.
- Drugmakers Fined $6M Over Viagra, Cialis, Levitra